Forte Biosciences, Inc.
FBRX
$11.16
-$0.10-0.89%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -13.75% | 61.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -28.19% | 119.34% | |||
| Operating Income | 28.19% | -119.34% | |||
| Income Before Tax | 28.15% | -118.81% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 28.15% | -118.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 28.15% | -118.81% | |||
| EBIT | 28.19% | -119.34% | |||
| EBITDA | 28.22% | -119.47% | |||
| EPS Basic | 30.27% | -17.62% | |||
| Normalized Basic EPS | 30.27% | -17.62% | |||
| EPS Diluted | 30.27% | -17.62% | |||
| Normalized Diluted EPS | 30.27% | -17.62% | |||
| Average Basic Shares Outstanding | 3.03% | 86.03% | |||
| Average Diluted Shares Outstanding | 3.03% | 86.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||